24.08.2012 - The US government will support Novozymes's partner Chemtex Inc. in its aim to construct a cellulosic ethanol plant in North Carolina by backing a US$99m loan.
The plant is expected to be located in Sampson County, North Carolina and produce 20 million gallons (76 million liters) of bioethanol per year from up to 600,000 tons of non-food grasses. The enzymes necessary for processing the biomass will be provided by Danish biotech company Novozymes (Baegsvaard). The construction is set to begin in late 2012. “Realising a commercial scale cellulosic ethanol plant in the United States and proving that it can produce cost competitive sustainable ethanol is an important milestone in the commercialisation process of advanced biofuels,” said Guido Ghisolfi, President of the Chemtex Group, which is a unit of the Italian chemical company Grupo Mossi & Ghisolfi.http://www.gruppomg.com/history.php?mi=201
Slated to open in 2014, the plant will employ approximately 65 employees and indirectly generate 250 more jobs in the community, not including construction jobs. The feedstock will be grown on low productivity/marginal land that is in part being utilised as “spray fields” for the hog farming industry. Wilmington, North Carolina-based Chemtex received US$3.9m from the US Department of Agriculture in Junehttp://www.chemtex.com/templates/news_20120613.html to grow more than 4,000 acres of miscanthus and switchgrass, which will now be used as feedstock. Chemtex and Novozymes have already started a collaboration this April aimed at building the world’s first industrial plant for fermentation of second generation bioethanol from cheap straw feeds.
26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.
24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.
23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.
17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.
13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.
13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.
10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.
10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.